Figure 6.

The effect of AF on SERCA and PLB. Representative immunoblots showing SERCA expression in (A) human LV myocardium from unused donor heart control (C), heart failure-SR, and heart failure-AF patients; (B) regularly paced vs. irregularly paced cardiomyocytes. Quantitative analysis of SERCA expression in (C) human myocardial samples (P < 0.05 control vs. AF; P < 0.01 SR vs. AF) and (D) isolated paced cardiomyocytes (*P < 0.05 regular vs. irregular). GAPDH indicates glyceraldehyde-3-phosphate dehydrogenase. Representative immunoblots showing PLB and phosphorylated-PLB expression in (E) human LV myocardium from unused donor heart control (C), heart failure-SR, and heart failure-AF patients; (F) regularly paced vs. irregularly paced cardiomyocytes. Quantitative analysis of phosphorylated : total PLB expression in (G) human myocardial samples (*P < 0.05 control vs. AF; **P < 0.01 SR vs. AF) and (H) isolated paced cardiomyocytes (*P < 0.05 regular vs. irregular). pSer, phosphoserine. Reproduced with permission from ref.²⁰